Daxor’s Blood Volume (BVA-100®) Diagnostic Demonstrates Clinical Utility In Critically-Ill COVID-19 Patients In Newly Published Data in Journal Critical Care Data Led to Multi-Center Study In Progress At Three Leading Hospitals Oak Ridge, TN, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume...

Daxor Corporation Receives National Institutes of Health (NIH) Funding Notification for Landmark Multi-Center Heart Failure Trial Utilizing the BVA-100® (Blood Volume Analyzer) with the United States Department of Veterans Affairs NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces the initiation of a multi-center clinical...

Newly Published Study Demonstrates Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Assessment of Postural Tachycardia Syndrome (POTS) NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the clinical utility...

Daxor Corporation Announces $0.48 Per Share NAV Increase and Files Annual Report for Fiscal 2020 Revenues of Operating Division Increase by 50.4% NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) The global leader in blood volume technology today filed its Annual...

Daxor Corporation Announces Pricing of $7.0 Million Registered Direct Offering NEW YORK, July 20, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE American: DXR) (“Daxor” or the “Company”), an investment company with innovative medical instrumentation and biotechnology...